NRW.BANK is investing in a seed financing round for Jülich-based start-up SRTD Biotech totalling 31.5 million euros. The start-up is using its technology to develop novel RNA-based drugs. The aim is to treat serious diseases more effectively and with fewer side effects in the future. SRTD Biotech plans to use the funding to advance the preclinical development of drug candidates for cancer, autoimmune diseases and fibrosis.
Read moreGlobal Finance’s 2026 ranking again features six EAPB direct members in the top ten.
Read moreAs part of the annual Supervisory Review and Evaluation Process (SREP), the European Central Bank has set the total SREP capital requirement for NWB Bank at 11%. The total SREP capital requirement is effective from 1 January 2027.
Read moreToday, Kommuninvest, which finances investments by Swedish municipalities and regions, publishes its second impact report* for Social Bonds**. The report presents results from social investments financed by Kommuninvest’s Social Sustainability Loans up to and including 31 December 2025. In total, the report covers 34 social investment projects in 24 municipalities, with approximately 860,000 people in the projects’ target groups.
KBN’s net interest income totalled NOK 633 million in the third quarter of 2026, compared to NOK 588 million in the same period in 2025.
Read moreLearn more about how we collect, store, use and disclose your personal data when you interact with us.
This Disclaimer is defined according to the European Regulation act of General Data Protection Regulation (2016/679).
We use this data for the purposes described in our policy, which include:
Learn more here https://eapb.eu/disclaimer.html